Cardiovascular Effects of COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

April 8, 2020

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions
COVID-19
Interventions
DRUG

AT-001

Investigational novel Aldose Reductase Inhibitor (ARI) Product: AT-001 500mg capsule for oral administration Dosage: 1,500mg (3X500mg capsules) twice daily Mode of Administration: Oral Up to 14 days per discretion of the investigators and treatment team

Trial Locations (1)

10016

NYU Langone Health, New York

All Listed Sponsors
lead

NYU Langone Health

OTHER